Join us for an Evening Symposium:
Unlocking Tomorrow's Care: The Power of Germline, Oncotype DX®, and Molecular Residual Disease (MRD) Testing in Shaping Personalized Breast Cancer Care
Wednesday, 4/10/2024, 7:00pm – 8:30pm ET
Location: Crystal J1 (Dinner will be provided)
Join speakers, Drs. Yao, Lipsyc-Sharf and Racz, as they review the expanded use of Oncotype DX Breast Recurrence Score® test in early-stage breast cancer patients, as well as the use of germline testing and molecular residual disease (MRD) in breast cancer patients.
Learning Objectives
- Recognize the expanded use of the Oncotype DX Breast Recurrence Score® test for decision-making in the adjuvant setting beyond systemic therapy
- Explore the rationale behind the recent ASCO recommendation for germline testing in breast cancer patients.
- Discuss the evolving role of molecular residual disease (MRD) testing in breast cancer patients.